These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3440100)

  • 1. Disposition of antipyrine in African patients with Hodgkin's lymphoma.
    Juma FD
    Br J Clin Pharmacol; 1987 Dec; 24(6):809-11. PubMed ID: 3440100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
    Wiela A; Orzechowska-Juzwenko K; Kotlarek-Haus S; Plamieniak B; Wolowiec D
    Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):562-5. PubMed ID: 3243660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ciprofloxacin on the pharmacokinetics of antipyrine in healthy volunteers.
    Tan KK; Allwood MC; Shawket S
    J Clin Pharm Ther; 1990 Apr; 15(2):151-4. PubMed ID: 2341493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of menstrual cycle on antipyrine pharmacokinetics in healthy Indian female volunteers.
    Nayak VK; Kshirsagar NA; Desai NK; Satoskar RS
    Br J Clin Pharmacol; 1988 Nov; 26(5):604-6. PubMed ID: 3207565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism.
    Caraco Y; Zylber-Katz E; Berry EM; Levy M
    Eur J Clin Pharmacol; 1995; 47(6):525-30. PubMed ID: 7768256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition.
    Greenblatt DJ; Divoll MK; Abernethy DR; Ochs HR; Harmatz JS; Shader RI
    Pharmacology; 1989; 38(5):327-34. PubMed ID: 2762375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers.
    He P; Liu GX; Liu ZH; Sun FY; Li CY; Yang Y
    Yao Xue Xue Bao; 1994; 29(8):566-9. PubMed ID: 7985514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.
    el-Raghy I; Back DJ; Osman F; Nafeh MA; Orme ML
    Br J Clin Pharmacol; 1985 Oct; 20(4):313-6. PubMed ID: 4074599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nifedipine on antipyrine and theophylline disposition.
    Adebayo GI; Mabadeje AF
    Biopharm Drug Dispos; 1990 Mar; 11(2):157-64. PubMed ID: 2183884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplified approaches to the determination of antipyrine pharmacokinetic parameters.
    Scavone JM; Greenblatt DJ; Blyden GT; Harmatz JS; Graziano PJ
    Br J Clin Pharmacol; 1988 Jun; 25(6):695-9. PubMed ID: 3203041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
    Abernethy DR; Egan JM; Dickinson TH; Carrum G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics.
    Knudsen JB; Bastain W; Sefton CM; Allen JG; Dickinson JP
    Xenobiotica; 1992 May; 22(5):579-89. PubMed ID: 1413873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
    Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
    Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine pharmacokinetics in women receiving conjugated estrogens.
    Scavone JM; Greenblatt DJ; Blyden GT
    J Clin Pharmacol; 1988 May; 28(5):463-6. PubMed ID: 3392245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs.
    KuKanich B; Coetzee JF; Gehring R; Hubin M
    J Vet Pharmacol Ther; 2007 Aug; 30(4):314-9. PubMed ID: 17610404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of fever on antipyrine metabolism in children.
    Forsyth JS; Moreland TA; Rylance GW
    Br J Clin Pharmacol; 1982 Jun; 13(6):811-5. PubMed ID: 7093111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of short-term starvation and water deprivation on pharmacokinetics of antipyrine in calves.
    Janus K
    Arch Vet Pol; 1992; 32(3-4):119-25. PubMed ID: 1339567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fenfluramine on disposition and rate of antipyrine elimination.
    O'Malley K; Stevenson IH; West M
    Pharmacology; 1975; 13(1):12-9. PubMed ID: 1153500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.